Advanced Research in Multiple Myeloma, Volume II
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 1326
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the Special Issue "Advanced Research in Multiple Myeloma" (https://www.mdpi.com/journal/cancers/special_issues/research_multiple_myeloma).
Multiple myeloma (MM) is the second most common hematological malignancy, with an incidence of 4.5–6 per 100,000 per year and a median age at diagnosis of 70 years. Although the use of high-dose therapy, autologous stem cell transplantation, and several new drugs (e.g., proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies) has led to significantly improved survival for MM patients, the majority will experience several relapses and will eventually die from the disease.
Trying to modify this evolution and aiming to cure the disease by understanding its pathogenesis, research in MM is currently focused on several aspects: 1) the role of genomic/epigenomic data and of specific modifications in the bone marrow microenvironment in the development of MM from its initial conditions (MGUS and smoldering MM) and in its ulterior clinical evolution; 2) the use of standard minimal residual disease (MRD) assessment (through next-generation sequencing, next-generation flow, and PET-CT) to assess treatment response and/or to guide the therapeutic schema in an attempt to optimize patient outcome (not only at diagnosis, but also in subsequent lines of therapy); 3) the use of alternative sources to assess MRD such as peripheral blood, and of alternative methods, including mass spectrometry, immune-based imaging, and DW-MRI; and 4) the clinical benefit, mechanisms of action, and resistance and determinants of response of the most advanced immune-based treatments applied at different time-points of the disease, including CAR-T cells and monoclonal antibodies.
To compile information regarding the most advanced myeloma research, we have planned this Special Issue of Cancers, to which we invite you to participate.
Dr. Noemí Puig
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- genomic/epigenomic
- minimal residual disease (MRD)
- alternative sources /methods
- immune-based treatments
